Results 181 to 190 of about 8,380,026 (270)

Case report: Complete response of recurrent locally advanced basal cell carcinoma following addition of vismodegib to neoadjuvant cemiplimab therapy. [PDF]

Front Oncol
Lambert-Swainston C, Samlowski W, Reynolds B, Hedayat A.   +3 more
europepmc   +1 more source

Tailored Toxicity-Driven Administration of Vismodegib in Patients With Multiple or Locally Advanced Basal Cell Carcinoma: A Pilot Analysis. [PDF]

Front Oncol, 2020
Tronconi MC, Solferino A, Giordano L, Borroni R, Mancini L, Santoro A.   +5 more
europepmc   +1 more source

Perioperative Avelumab and Chemotherapy for Gastroesophageal Adenocarcinoma: Long‐Term Survival Outcomes

International Journal of Cancer, EarlyView.
ABSTRACT Long‐term survival data for patients with locally advanced gastro‐esophageal adenocarcinoma (GEA) treated with neoadjuvant chemoimmunotherapy are lacking. We describe the long‐term disease‐free survival (DFS) and overall survival (OS) outcomes of such patients treated with a novel neoadjuvant chemoimmunotherapy regimen, aDCF (avelumab with ...
Thierry Alcindor, James Tankel, Pierre‐Olivier Fiset, Mehrnoush Dehghani, Nicholas Bertos, Carmen Mueller, Jonathan Cools‐Lartigue, Sophie Camilleri‐Broet, Lorenzo Ferri   +8 more
wiley   +1 more source

Imaging in Locally Advanced and Metastatic Basal Cell Carcinoma: Findings and Recommendations

EJC Skin Cancer
A. Zwanenburg, W. Van Houdt, M. Schrijver, B. Van der Hiel, B. Seinstra, W. Schreuder, M. Wouters, E. Plasmeijer   +7 more
doaj   +1 more source

Quality of life in cemiplimab-treated patients with locally advanced basal cell carcinoma in a Phase II clinical trial. [PDF]

Future Oncol
Stratigos AJ, Chen CI, Ivanescu C, Lewis KD, Peris K, Bechter O, Harnett J, Mastey V, Reaney M, Daskalopoulou C, LaFontaine PR, Konidaris G, Bury D, Yoo SY, Mohan K, Coates E, Bowler T, Fury MG, Sekulic A.   +18 more
europepmc   +1 more source

Real‐World Experience With Multimodal Treatment of Resectable Stage II–III Non‐Small Cell Lung Cancer: A Single Institutional Analysis

International Journal of Cancer, EarlyView.
ABSTRACT Neoadjuvant therapy has recently become an integral component of multimodal treatment for resectable lung cancer. However, real‐world data on perioperative morbidity and treatment adherence remain limited. This study aimed to assess the feasibility and safety of different neoadjuvant treatment approaches applied within daily clinical routine ...
Raffaella Griffo, Benedikt Niedermaier, Laura V. Klotz, Marc Schneider, Michael Allgäuer, Marc Kriegsmann, Romina M. Roesch, Lena Brendel, Henrike Deissner, Farastuk Bozorgmehr, Petros Christopoulos, Michael Thomas, Hauke Winter, Martin E. Eichhorn, Florian Eichhorn   +14 more
wiley   +1 more source

Combined cryotherapy and topical imiquimod, 5-fluorouracil, and tazarotene effectively treats locally advanced basal cell carcinoma and is associated with nearby nodular basal carcinoma regression. [PDF]

JAAD Case Rep
Nahm WJ, Shen OL, Kirsner RS, Mathe CA, Nikas OV, Valadez FD, Badiavas EV.   +6 more
europepmc   +1 more source

Neoadjuvant anti-programmed cell death 1 therapy for locally advanced basal cell carcinoma in treatment-naive patients: A case series. [PDF]

JAAD Case Rep, 2020
Ligtenberg KG, Hu JK, Damsky W, Olino K, Kluger H, Clune J, Cowper SE, Panse G, Leventhal J, Weiss SA.   +9 more
europepmc   +1 more source

Clinical Outcomes of Gemcitabine Plus Nab‐Paclitaxel‐Based Chemoradiotherapy in a Multidisciplinary Treatment Strategy for Locally Advanced Pancreatic Cancer (NUPAT‐05): A Prospective, Single‐Arm, Phase II Study

International Journal of Cancer, EarlyView.
ABSTRACT Although chemoradiotherapy (CRT) has exhibited activity against locally advanced pancreatic cancer (LAPC), no standard regimen has been established. We previously completed a Phase I trial of CRT with gemcitabine plus nab‐paclitaxel (GnP) and established the recommended dose.
Hironori Yamada, Haruyoshi Tanaka, Suguru Yamada, Hideki Takami, Masamichi Hayashi, Nobuhiko Nakagawa, Keisuke Kurimoto, Yoshikuni Inokawa, Nobuyuki Watanabe, Takuya Ishikawa, Masayuki Okumura, Hiroshi Ogawa, Masahiko Ando, Osamu Maeda, Junpei Yamaguchi, Shinji Naganawa, Hiroki Kawashima, Tsutomu Fujii, Yukihiro Yokoyama, Tomoki Ebata, Mitsuro Kanda   +20 more
wiley   +1 more source

The Use of Combination Palliative Radiotherapy and Single‐Agent Immunotherapy for the Management of Head and Neck Squamous Cell Carcinoma (HNSCC) in the United Kingdom (UK)

International Journal of Cancer, EarlyView.
ABSTRACT Clinical data on combined Immunotherapy (IO) and palliative radiotherapy (RT) in HNSCC is scarce. HNSCC Palliative RT differs from curative intent RT as it does not involve elective nodal irradiation; therefore, an immune response may be more likely.
Chris Hurt, Sarah Park, Jonathan Chambers, Caroline Brammer, Matthew Griffin, Vishnu Harilal, Ruth Stone, Puteri Abdul Haris, Rebecca Shakir, Louise Karsera, Will Ince, Femi Adeoye, Daljit Gahir, James Lester, Ehiosa Charles Okuofo, Saira Khalique, Mayumi Forster, Philippa Smith, Oliver Donnelly, Lyndon Ridges‐Jones, James Hesford, Naomi Cole   +21 more
wiley   +1 more source